Business- Page 103

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License

New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN), a hematology-focused

Verizon Powers the 2026 NFL Season with Stadium Upgrades and Global Private Wireless Network At a Glance Connected Officiating: Officials use league-issued connected watches powered by Verizon’s private wireless network to receive

— Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations — — Trial-in-progress presentation to highlight

Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site

Former Qualtrics Chief Transformation Officer joins the AvePoint Executive Leadership Team to deepen customer value and accelerate growth as enterprises scale AI with trust JERSEY CITY, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE)

Conditional agreement covering 52 wells could generate more than $2 million in annual service revenue for Direct Midstream at targeted operating levels Dallas, TX, Nov. 04, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc.

– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including

− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with relapsed/refractory monocytic AML

Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID)